Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia

Table 1

Molecular classification of CN-AML and clinical outcomes.

AML with NPM1 mutation
NPM1	Better EFS and OS [29–32]; better CRR, high RR with EFS or OS benefits [33]; better OS [34]
NPM1/DNMT3A	Worse OS [41]
NPM1/DNMT3A/FLT3	Worse OS [18]
NPM1/DNMT3A/NRAS	Better OS [18]
NPM1/TET2	Worse CRR, EFS, DFS, and OS [50]; no impact on outcomes [41]
NPM1/IDH1 or NPM1/IDH2	Worse OS [55]; better OS [27, 52]
AML with mutated chromatin, RNA-splicing genes, or both
RUNX1	Worse EFS, DFS [59, 61, 62]; worse OS [59–62]
MLL	Worse EFS [60, 66, 67]; worse OS [27, 41, 60, 67]
ASXL1	Worse outcomes [27, 60, 75]; worse CR, EFS, DFS, and OS [77]
BCOR	Worse EFS and OS [81]
PHF6	Worse OS [27]
AML with CEBPA mutation
CEBPA	Better EFS and OS [86]
CEBPA/TET2	Worse OS [89]
CEBPA/GATA2	Better OS [89]
AML with IDH2 mutation	Worse RR and OS [52, 90]; better OS [18]

EFS: event-free survival; OS: overall survival; CRR: complete remission rate; RR: relapse rate; DFS: disease-free survival.
Without FLT3.